

**Certificate of Mailing**

Express Mail Label No.: EV 312852905 US

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 and is addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

By: Barbara Bryant  
Barbara Bryant

Date: July 25, 2003

Patent  
Attorney's Docket No. P-154-US1

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of	)	
	)	
MORAN et al.	)	Group Art Unit: Not yet assigned
	)	
Application No.: Not yet assigned	)	Examiner: Not yet assigned
	)	
Filed: Even date herewith	)	
	)	
For: CRYSTALLINE $\beta_2$ ADRENERGIC	)	
RECEPTOR AGONIST	)	
	)	

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure as set forth in 37 CFR §1.56, Applicants hereby submit the following information in conformance with CFR §§1.97 and 1.98. Enclosed herewith is form PTO-1449 which lists documents for consideration by the Examiner. Copies of the cited documents are also enclosed herewith.

The filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made (37 C.F.R. §1.97(g)), or as an admission that the information cited is, or is considered to be, material to patentability (37 C.F.R. §1.97(h)).

Consideration of the listed documents is respectfully requested. Additionally, the Examiner is respectfully requested to return an initialed copy of the enclosed form PTO-1449 to Applicants.

This Information Disclosure Statement is being filed before the mailing date of a first official action on the merits for this RCE application and therefore, no fee or certification is required under 37 CFR §1.97(b). In the event that an Office Action is mailed prior to receipt of this paper, the Commissioner is hereby authorized to charge the requisite fees under 37 CFR §1.97(c) for submission of this paper to Deposit Account No. 50-0344.

Should there be any questions concerning the cited documents, the Examiner is encouraged to telephone the undersigned agent for Applicants at (650) 808-3764 (direct).

Respectfully submitted,

THERAVANCE, INC.

Date: July 23, 2003

By: Roberta P. Saxon  
Roberta P. Saxon, Ph.D.  
Registration No. 43,087

THERAVANCE, INC.  
901 Gateway Boulevard  
South San Francisco, CA 94080  
Tel: (650) 808-6000  
Fax: (650) 808-6078

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number	Not yet assigned
Filing Date	July 25, 2003
First Named Inventor	Martin S. LINSELL
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	P-154-US1

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	A1	US-5,225,183	07-06-1993	Purewal et al.	
	A2	US- 5,980,867	11-09-1999	Tzou et al.	
	A3	US- 6,040,344	03-21-2000	Gao et al.	
	A4	US- 6,143,277	11-07-2000	Ashurst et al.	
	A5	US- 6,541,669 B1	04-01-2003	Moran et al.	
	A6	US- 6,576,793 B1	06-10-2003	Moran et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	B1	WO 92/22286	12-23-1992	Minnesota Mining and Manufacturing Company		
	B2	WO 99/53901	10-28-1999	Glaxo Group Limited		
	B3	WO 00/61108	10-19-2000	Glaxo Group Limited		
	B4	WO 02/066422 A1	08-29-2002	Glaxo Group Limited		
	B5	WO 02/076933 A1	10-03-2002	Glaxo Group Limited		
	B6	EP 0 717 987 A2	06-26-1996	Minnesota Mining and Manufacturing Company		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.